Table 2.
Complete response, complete protection, and total control rates in intention-to-treat population
| Phase | No. (%) |
Differencea) (95% CI) | |
|---|---|---|---|
| RAD (n=137) | PAD (n=142) | ||
| CR | |||
| Acute | 131 (95.6) | 133 (93.7) | 2.0 (−3.3 to 7.2) |
| Delayed | 115 (83.9) | 113 (79.6) | 4.4 (−4.7 to 13.4) |
| Overall | 112 (81.8) | 113 (79.6) | 2.2 (−7.1 to 11.4) |
| CP | |||
| Acute | 105 (76.6) | 111 (78.2) | −1.5 (−11.3 to 8.3) |
| Delayed | 82 (59.9) | 89 (62.7) | −2.8 (−14.3 to 8.6) |
| Overall | 77 (56.2) | 83 (58.5) | −2.3 (−13.9 to 9.4) |
| TC | |||
| Acute | 94 (68.6) | 91 (64.1) | 4.5 (−6.6 to 15.6) |
| Delayed | 67 (48.9) | 66 (46.5) | 2.4 (−9.3 to 14.2) |
| Overall | 65 (47.5) | 62 (43.7) | 3.8 (−7.9 to 15.5) |
RAD, ramosetron, aprepitant, and dexamethasone; PAD, palonosetron, aprepitant, and dexamethasone; 95% CI, 95% confidence interval; CR, complete response; CP, complete protection; TC, total control.
a)
Difference was calculated as (RAD-PAD).